SRF617 + pembrolizumab

SRF617 + pembrolizumab is a combination of two distinct monoclonal antibodies investigated for the treatment of advanced solid tumors, particularly in patients with gastric cancer and those resistant to previous immune checkpoint inhibitor therapies. **SRF617** is a human monoclonal antibody that targets the enzyme CD39, which regulates extracellular adenosine and ATP levels in the tumor microenvironment. By blocking CD39, SRF617 reduces immunosuppressive adenosine levels and promotes antitumor immune responses. **Pembrolizumab** is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance T-cell activity against cancer cells. The combination is designed to synergistically activate both the innate and adaptive immune system arms, potentially overcoming resistance to anti-PD-1 therapy and improving antitumor immunity. Clinical trials are ongoing to assess safety, pharmacokinetics, and preliminary efficacy of this combination in advanced solid tumors[1][2][3][5].

Brand names

Keytruda

Other names

SRF617 + Keytruda